SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 350.80 |
| Enterprise Value ($M) | 80.66 |
| Book Value ($M) | 364.47 |
| Book Value / Share | 4.29 |
| Price / Book | 0.96 |
| NCAV ($M) | 362.74 |
| NCAV / Share | 4.27 |
| Price / NCAV | 0.97 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.24 |
| Return on Assets (ROA) | -0.33 |
| Return on Equity (ROE) | -0.34 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 32.99 |
| Current Ratio | 32.99 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 376.51 |
| Assets | 378.23 |
| Liabilities | 13.76 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Citadel Advisors Llc | |||
| 13G/A | Schonfeld Strategic Advisors LLC | |||
| 13G/A | Soleus Capital Master Fund, L.P. | |||
| 13G/A | BlackRock, Inc. | |||
| 13G/A | Vivo Capital Fund VIII, L.P. | 5.40 | ||
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 4.99 | -21.80 | |
| 13G/A | Fairmount Funds Management LLC | 0.00 | -100.00 | |
| 13G/A | Suvretta Capital Management, Llc | 0.00 | -100.00 | |
| 13G/A | Point72 Asset Management, L.P. | 3.50 | -26.19 | |
| 13G/A | Integrated Core Strategies (us) Llc | 1.90 | -53.20 | |
| 13D/A | Orbimed Advisors Llc | 9.00 | 0.00 | |
| 13G/A | Deep Track Capital, LP | 9.87 | 71.35 | |
| 13G/A | LAV Biosciences Fund V, L.P. | 4.70 | 0.00 | |
| 13G/A | Fmr Llc | 4.84 | -41.57 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| i UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 232,987 | 928,822 | 25.08 | |
| 108,250 | 852,524 | 12.70 | |
| 302,165 | 981,917 | 30.77 | |
| 224,805 | 1,015,545 | 22.14 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SYRS – Syros Pharmaceuticals, Inc. | TARS – Tarsus Pharmaceuticals, Inc. |
| TECH – Bio-Techne Corporation | TLRY – Tilray Brands, Inc. |
| TNYA – Tenaya Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io